Company: INSP
Filing Date: 2025-02-10
Form Type: 10-K
Source: 0001609550-25-000011
Chunk: 36

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-02-10
Form: 10-K
Item: Item 1
Chunk 36
---
 (tirzepatide), was FDA approved for treatment of OSA in patients with obesity and moderate to severe OSA. We believe other emerging businesses are in the early stages of developing alternative OSA treatment therapies or early-stage pharmaceutical approaches.

We believe that the primary competitive factors in the OSA treatment market are:

•company, product, and brand recognition;

•product safety, efficacy, reliability, and durability;

•quality and volume of clinical data;

•effective marketing to and education of patients, physicians, and sleep centers;

•product ease of use and patient comfort;

•sales force experience and access;

•product support and service;

•technological innovation, product enhancements, and speed of innovation;

•pricing and revenue strategies;

•procedure costs to patients;

•effectiveness of reimbursement teams and strategies; and

•dedicated practice development and clinical training teams.

We also compete with other medical technology companies to recruit and retain qualified personnel.

Intellectual Property

We rely on a combination of patent, copyright, trademark and trade secret laws, and confidentiality and invention assignment agreements to protect our intellectual property rights. As of December 31, 2024, we had rights to 98 issued U.S. patents, which will expire between 2029 and 2041 assuming all required fees are paid, 67 pending U.S. patent applications, 72 issued foreign patents, and 69 pending foreign patent applications. Our patents cover aspects of our current Inspire system and future product concepts. Some of the issued foreign patents and pending foreign patent applications preserve an opportunity to pursue patent rights in multiple countries.

There is no active patent litigation involving any of our patents and we have not received any notices of patent infringement.

As of December 31, 2024, we had 165 pending and registered trademark filings worldwide, some of which may apply to multiple countries.

We also rely, in part, upon unpatented trade secrets, know-how and continuing technological innovation, and may in the future rely upon licensing opportunities, to develop and maintain our competitive position. We protect our proprietary rights through a variety of methods, including confidentiality and assignment agreements with suppliers, employees, consultants, and others who may have access to our proprietary information.

Our pending patent applications may not result in issued patents, and we cannot ensure that any current or subsequently issued patents will adequately protect our products or provide us with any competitive advantage. 

18

While there is no active litigation involving any of our patents or other intellectual property rights and we have not received any notices of patent